• The ORR and CR rates at completion of PET-adapted Nivo/Nivo+ NICE were 93% and 91%.

  • Two-year PFS in all patients was 72%, and 94% in the 33 patients who bridged directly to AHCT after protocol therapy (26 after Nivo only).

This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in relapsed/refractory (RR) classical Hodgkin lymphoma (cHL). Patients with RR cHL received 240 mg nivolumab every 2 weeks for up to 6 cycles (C). Patients in complete response (CR) after C6 proceeded to AHCT, whereas patients with progressive disease at any point or not in CR after C6 received NICE for 2 cycles. The primary endpoint was CR rate per the 2014 Lugano classification at completion of protocol therapy. Forty-three patients were evaluable for toxicity; 42 were evaluable for response. Thirty-four patients received nivolumab alone, and 9 patients received nivolumab+NICE. No unexpected toxicities were observed after nivolumab or NICE. After nivolumab, the overall response rate (ORR) was 81%, and the CR rate was 71%. Among 9 patients who received NICE, all responded, with 8 (89%) achieving CR. At the end of protocol therapy, the ORR and CR rates were 93% and 91%. Thirty-three patients were bridged directly to AHCT, including 26 after Nivo alone. The 2-year progression-free survival (PFS) and overall survival in all treated patients (n = 43) were 72% and 95%, respectively. Among 33 patients who bridged directly to AHCT, the 2-year PFS was 94% (95% CI: 78-98). PET-adapted sequential salvage therapy with nivolumab/nivolumab+NICE was well tolerated and effective, resulting in a high CR rate and bridging most patients to AHCT without chemotherapy. This trial was registered at www.clinicaltrials.gov #NCT03016871.

1.
Armitage
JO
.
Early-stage Hodgkin’s lymphoma
.
N Engl J Med.
2010
;
363
(
7
):
653
-
662
.
2.
Engert
A
,
Diehl
V
,
Franklin
J
, et al
.
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study
.
J Clin Oncol.
2009
;
27
(
27
):
4548
-
4554
.
3.
Press
OW
,
Li
H
,
Schöder
H
, et al
.
US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816
.
J Clin Oncol.
2016
;
34
(
17
):
2020
-
2027
.
4.
Johnson
P
,
Federico
M
,
Kirkwood
A
, et al
.
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma
.
N Engl J Med.
2016
;
374
(
25
):
2419
-
2429
.
5.
Radford
J
,
Illidge
T
,
Counsell
N
, et al
.
Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma
.
N Engl J Med.
2015
;
372
(
17
):
1598
-
1607
.
6.
Linch
DC
,
Winfield
D
,
Goldstone
AH
, et al
.
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial
.
Lancet.
1993
;
341
(
8852
):
1051
-
1054
.
7.
Schmitz
N
,
Pfistner
B
,
Sextro
M
, et al;
Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
.
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial
.
Lancet.
2002
;
359
(
9323
):
2065
-
2071
.
8.
Morschhauser
F
,
Brice
P
,
Fermé
C
, et al;
GELA/SFGM Study Group
.
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group
.
J Clin Oncol.
2008
;
26
(
36
):
5980
-
5987
.
9.
Moskowitz
CH
,
Nademanee
A
,
Masszi
T
, et al;
AETHERA Study Group
.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
.
Lancet.
2015
;
385
(
9980
):
1853
-
1862
.
10.
Moskowitz
CH
,
Walewski
J
,
Nademanee
A
, et al
.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
.
Blood.
2018
;
132
(
25
):
2639
-
2642
.
11.
Moskowitz
AJ
,
Yahalom
J
,
Kewalramani
T
, et al
.
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
.
Blood.
2010
;
116
(
23
):
4934
-
4937
.
12.
Devillier
R
,
Coso
D
,
Castagna
L
, et al
.
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy
.
Haematologica.
2012
;
97
(
7
):
1073
-
1079
.
13.
Akhtar
S
,
Al-Sugair
AS
,
Abouzied
M
, et al
.
Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT
.
Bone Marrow Transplant.
2013
;
48
(
12
):
1530
-
1536
.
14.
Gentzler
RD
,
Evens
AM
,
Rademaker
AW
, et al
.
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
.
Br J Haematol.
2014
;
165
(
6
):
793
-
800
.
15.
Moskowitz
CH
,
Nimer
SD
,
Zelenetz
AD
, et al
.
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
.
Blood.
2001
;
97
(
3
):
616
-
623
.
16.
Josting
A
,
Rudolph
C
,
Reiser
M
, et al;
Participating Centers
.
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease
.
Ann Oncol.
2002
;
13
(
10
):
1628
-
1635
.
17.
Santoro
A
,
Magagnoli
M
,
Spina
M
, et al
.
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma
.
Haematologica.
2007
;
92
(
1
):
35
-
41
.
18.
Baetz
T
,
Belch
A
,
Couban
S
, et al
.
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
.
Ann Oncol.
2003
;
14
(
12
):
1762
-
1767
.
19.
Bartlett
NL
,
Niedzwiecki
D
,
Johnson
JL
, et al;
Cancer Leukemia Group B
.
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804
.
Ann Oncol.
2007
;
18
(
6
):
1071
-
1079
.
20.
Santoro
A
,
Mazza
R
,
Pulsoni
A
, et al
.
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study
.
J Clin Oncol.
2016
;
34
(
27
):
3293
-
3299
.
21.
Moskowitz
AJ
,
Schöder
H
,
Yahalom
J
, et al
.
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study
.
Lancet Oncol.
2015
;
16
(
3
):
284
-
292
.
22.
Chen
R
,
Palmer
JM
,
Martin
P
, et al
.
Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma
.
Biol Blood Marrow Transplant.
2015
;
21
(
12
):
2136
-
2140
.
23.
Herrera
AF
,
Palmer
J
,
Martin
P
, et al
.
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
.
Ann Oncol.
2018
;
29
(
3
):
724
-
730
.
24.
Cassaday
RD
,
Fromm
J
,
Cowan
AJ
, et al
.
Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I/II trial [abstract]
.
Blood.
2016
;
128
(
22
). Abstract
1834
.
25.
Stamatoullas
A
,
Ghesquieres
H
,
Clement filliatre
L
, et al
.
Brentuximab vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study [abstract]
.
Blood.
2019
;
134
(
suppl 1
). Abstract
132
.
26.
Garcia-Sanz
R
,
Sureda
A
,
de la Cruz
F
, et al
.
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
.
Ann Oncol.
2019
;
30
(
4
):
612
-
620
.
27.
Hagenbeek
A
,
Zijlstra
JM
,
Plattel
WJ
, et al
.
Combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study [abstract]
.
Blood.
2018
;
132
(
suppl 1
). Abstract
2923
.
28.
Cole
PD
,
McCarten
KM
,
Pei
Q
, et al
.
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial
.
Lancet Oncol.
2018
;
19
(
9
):
1229
-
1238
.
29.
LaCasce
AS
,
Bociek
RG
,
Sawas
A
, et al
.
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
.
Blood.
2018
;
132
(
1
):
40
-
48
.
30.
Armand
P
,
Engert
A
,
Younes
A
, et al
.
Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial [published correction appears in J Clin Oncol. 2018;36(26):2748]
.
J Clin Oncol.
2018
;
36
(
14
):
1428
-
1439
.
31.
Armand
P
,
Kuruvilla
J
,
Michot
J-M
, et al
.
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure
.
Blood Adv.
2020
;
4
(
12
):
2617
-
2622
.
32.
Chen
R
,
Zinzani
PL
,
Fanale
MA
, et al;
KEYNOTE-087
.
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma
.
J Clin Oncol.
2017
;
35
(
19
):
2125
-
2132
.
33.
Younes
A
,
Santoro
A
,
Shipp
M
, et al
.
Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
.
Lancet Oncol.
2016
;
17
(
9
):
1283
-
1294
.
34.
Herrera
AF
,
Moskowitz
AJ
,
Bartlett
NL
, et al
.
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
.
Blood.
2018
;
131
(
11
):
1183
-
1194
.
35.
Advani
RH
,
Moskowitz
AJ
,
Bartlett
NL
, et al
.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
.
Blood.
2021
;
138
(
6
):
427
-
438
.
36.
Spitzer
TR
.
Engraftment syndrome following hematopoietic stem cell transplantation
.
Bone Marrow Transplant.
2001
;
27
(
9
):
893
-
898
.
37.
Cheson
BD
,
Fisher
RI
,
Barrington
SF
, et al;
United Kingdom National Cancer Research Institute
.
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
.
J Clin Oncol.
2014
;
32
(
27
):
3059
-
3068
.
38.
Simon
R
.
Optimal two-stage designs for phase II clinical trials
.
Control Clin Trials.
1989
;
10
(
1
):
1
-
10
.
39.
Herrera
AF
,
Palmer
J
,
Adhikarla
V
, et al
.
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
.
Blood Adv.
2021
;
5
(
23
):
5300
-
5311
.
40.
Herrera
AF
,
Chen
L
,
Popplewell
LL
, et al
.
Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma [abstract]
.
Blood.
2019
;
134
(
suppl 1
). Abstract
759
.
41.
Abramson
JS
,
Arnason
JE
,
LaCasce
AS
, et al
.
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
.
Blood.
2019
;
134
(
7
):
606
-
613
.
42.
Moskowitz
AJ
,
Shah
G
,
Schöder
H
, et al
.
Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
.
J Clin Oncol.
2021
;
39
(
28
):
3109
-
3117
.
43.
Bryan
LJ
,
Smith
SE
,
Allen
P
, et al
.
Safety and toxicity profile of pembrolizumab (PEM) in combination with ICE chemotherapy followed by autologous stem cell transplantation for relapsed/refractory classical Hodgkin lymphoma: no impairment in stem cell mobilization or engraftment [abstract]
.
Blood.
2019
;
134
(
suppl 1
). Abstract
4029
.
44.
Merryman
RW
,
Redd
RA
,
Nishihori
T
, et al
.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
.
Blood Adv.
2021
;
5
(
6
):
1648
-
1659
.
45.
Song
MK
,
Chung
JS
,
Lee
JJ
, et al
.
Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma
.
Cancer Sci.
2013
;
104
(
12
):
1656
-
1661
.
46.
Kanoun
S
,
Rossi
C
,
Berriolo-Riedinger
A
, et al
.
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
.
Eur J Nucl Med Mol Imaging.
2014
;
41
(
9
):
1735
-
1743
.
47.
Tseng
D
,
Rachakonda
LP
,
Su
Z
, et al
.
Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin’s disease
.
Radiat Oncol.
2012
;
7
(
1
):
5
.
48.
Hussien
AE
,
Furth
C
,
Schönberger
S
, et al
.
FDG-PET response prediction in pediatric Hodgkin’s lymphoma: impact of metabolically defined tumor volumes and individualized SUV measurements on the positive predictive value
.
Cancers (Basel).
2015
;
7
(
1
):
287
-
304
.
49.
Cottereau
AS
,
Versari
A
,
Loft
A
, et al
.
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
.
Blood.
2018
;
131
(
13
):
1456
-
1463
.
50.
Moskowitz
AJ
,
Schöder
H
,
Gavane
S
, et al
.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
.
Blood.
2017
;
130
(
20
):
2196
-
2203
.
51.
Mettler
J
,
Muller
H
,
Voltin
CA
, et al
.
Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma
.
J Nucl Med.
2018
;
60
(
2
):
207
-
211
.
52.
Casasnovas
RO
,
Kanoun
S
,
Tal
I
, et al
.
Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial [abstract]
.
J Clin Oncol.
2016
;
34
(
15
). Abstract
7509
.
53.
Kanoun
S
,
Tal
I
,
Berriolo-Riedinger
A
, et al
.
Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma
.
PLoS One.
2015
;
10
(
10
):
e0140830
.
54.
Voltin
CA
,
Mettler
J
,
van Heek
L
, et al
.
Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial
.
Clin Cancer Res.
2021
;
27
(
2
):
402
-
407
.
55.
Allen
PB
,
Savas
H
,
Evens
AM
, et al
.
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
.
Blood.
2021
;
137
(
10
):
1318
-
1326
.
56.
Carey
CD
,
Gusenleitner
D
,
Lipschitz
M
, et al
.
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
.
Blood.
2017
;
130
(
22
):
2420
-
2430
.
You do not currently have access to this content.

Sign in via your Institution